Evelo Biosciences Provides Clinical and Business Updates

– Data from first three cohorts of EDP1815 Phase 2 trial in atopic dermatitis did not meet primary endpoint; unusually high placebo response rate observed –
– Clear path to registration trials for EDP1815 in psoriasis based on recently completed interactions with FDA, EMA and MHRA –
– Dosing commenced in clinical study with first extracellular vesicle (EV) product candidate EDP2939 in January; Phase 2 data in psoriasis anticipated in 2H 2023 –
– Optimizing operations and reducing workforce to focus resources on strategic priorities –
– CEO Simba Gill, Ph.D., will continue to lead the organization, halting search for successor –
– Management to host conference call today at 8:30 a.m. ET –

Read more at globenewswire.com

Related news for (EVLO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.